Understanding the physiological changes induced by mannitol: From the theory to the clinical practice in neuroanaesthesia

Wilson Fandino

Abstract

In this narrative review, the current evidence for the use of mannitol in neuroanaesthesia is presented, with focus on its pharmacokinetics and its main physiologic effects. Mannitol is a naturally occurring polyol that undergoes no biotransformation and is freely filtered in the kidney. Due to its strong osmotic effects, it induces key physiological changes, mainly in the cardiovascular system, the kidney and the brain. While it is clear that hypertonic solutions are effective in the treatment of intracranial hypertension in patients with acute brain injury, the role of mannitol in the context of intracranial haemorrhage, acute stroke and brain relaxation remains controversial. Furthermore, it possesses important side effects including acute kidney injury and electrolyte imbalances, particularly related to high doses in predisposing patients. Other aspects including the capability to modify neurological outcomes, the impact on mortality, the utility in patients with disrupted blood–brain barrier and the alternative use of hypertonic saline are also discussed. Further research is needed to make clear recommendations on these aspects.

Key words: Intracranial hypertension, mannitol, osmotic diuresis, traumatic brain injury

INTRODUCTION

Since first introduced in 1940 for exploring the glomerular filtration rate in humans,²⁴ mannitol has been used in several clinical scenarios. This osmotic agent is useful as a diuretic in the context of crush injury, compartment syndrome and intoxications (e.g., barbiturate, salicylate, bromide), preventing acute renal failure following rhabdomyolysis, and as a hypertonic solution in the treatment of intraocular and intracranial hypertension. It has also been used for exploring the mechanisms of tubular reabsorption of water and salt at the nephron, optimising the cardiac preload and contractility, relief of the swelling on the endothelial cell following brief periods of vascular occlusion in heart, kidney and brain, preparation for bowel surgery and as a dialyser in diabetic patients undergoing peritoneal dialysis.²⁴

Mannitol is included in the World Health Organisation’s list of essential medicines⁵ and has been widely used in neuroanaesthesia, as it is considered to be a safe medication and one of the cornerstones in the treatment of the elevated intracranial pressure (ICP). However, the evidence supporting its use is scarce, the heterogeneity in the dosages used makes it difficult to establish an optimal treatment regimen, the clinical utility in patients with disrupted blood–brain barrier (BBB) is debatable and the impact on the neurological outcomes and mortality remains unknown. Furthermore, it can cause serious
complications, particularly related to cardiovascular changes, electrolyte disturbances and renal damage in patients with predisposing factors. Therefore, in this review, the main pharmacologic and physiological effects are revisited, along with the current evidence for its use in neuroanaesthesia, including its utility for the ICP management and brain relaxation.

PHARMACOLOGY

Mannitol (C₆H₁₄O₆) is a naturally occurring 6-carbon polyol, isomer of sorbitol, produced by several microorganisms and plants and found in several fruits and vegetables. It is a naturally occurring compound and is produced industrially from the hydrogenation of fructose and glucose and from biological sources.

As a sugar alcohol, mannitol has a sweet taste. This property has been used by food and pharmaceutical industries for masking bitter tastes. At room temperature, it may crystallise, making it unsuitable for administration. In this case, warming the solution solves the problem. In many countries, 10% and 20% solutions are available for clinical use, providing 100 and 200 g/L, respectively.

Table 1 provides the main physical and pharmacokinetic properties. Hypertonic mannitol (20%) has an osmolarity approximately equivalent to that provided by 3.2% hypertonic saline. When administered orally, it is minimally absorbed and nearly 75% undergo fermentation by the intestinal flora. Due to its scanty absorption, it has been used for routine preparation of bowel surgery. When administered intravenously, it distributes primarily in the extracellular compartment and is excreted unchanged in urine. Thus, 90% of the injected dose is recoverable in the urine during the first 24 h.

MANNITOL AND THE CARDIOVASCULAR SYSTEM

The haemodynamic response when administered intravenously is typically triphasic. Approximately 15 min after starting the infusion, it first induces a sharp elevation in the serum osmolarity, resulting in a transient increase in blood volume, which in turn raises cardiac output (CO) and pulmonary capillary wedge pressure (PCWP). Accordingly, it can elicit cardiogenic and pulmonary oedema in high-risk patients. Therefore, mannitol should be administered cautiously in patients with congestive heart failure or pre-existing renal insufficiency, and when Loop of Henle (LH) diuretics are concomitantly administered. During the second phase, the blood volume, CO and PCWP drop below initial values after 45 min, due to its diuretic effect and peripheral vasodilation. The latter occurs primarily in the skeletal muscle and leads to marked hypotension, particularly when mannitol is administered at high rates. These changes may be also associated with a small increase in blood lactate levels. Finally, during the third phase, these haemodynamic variables return to the baseline values.

Since mannitol has a strong diuretic effect, efforts should be made to avoid arterial hypotension and constant monitoring of the cerebral perfusion pressure (CPP) is recommended. Owing to its high osmolarity, when administered through a peripheral line, it can induce phlebitis and skin necrosis may occur in cases of extravasation. Therefore, careful examination of the peripheral vein should be done before, during and after its administration.

MANNITOL AND THE KIDNEY

Due to its small molecular weight, it is readily filtered in the glomerulus. Then, it decreases the water reabsorption in the proximal tubule, thereby diminishing the sodium concentration. The water reabsorption also decreases in the descending limb of the LH, whereas the sodium reabsorption is progressively reduced in the ascending limb and the collecting tube.

Table 1: Physical and pharmacokinetic properties of mannitol

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>182 Daltons</td>
</tr>
<tr>
<td>Osmolarity (20%)</td>
<td>1098 mOsm/L</td>
</tr>
<tr>
<td>Volume of distribution</td>
<td>0.471 L/kg</td>
</tr>
<tr>
<td>Onset</td>
<td>≈15 min</td>
</tr>
<tr>
<td>Maximal effect</td>
<td>≈45 min</td>
</tr>
<tr>
<td>Duration</td>
<td>≈6 h</td>
</tr>
<tr>
<td>Half-life</td>
<td>70-100 min</td>
</tr>
<tr>
<td>Biotransformation</td>
<td>None</td>
</tr>
<tr>
<td>Excretion</td>
<td>Renal</td>
</tr>
<tr>
<td>Reabsorption</td>
<td>7%</td>
</tr>
</tbody>
</table>

Figure 1: Chemical structure of mannitol
Although its effects are mainly exerted in the renal tubules, other mechanisms are also important. As an impermeant solute mainly distributed in the extracellular compartment, it increases the osmotic pressure, promotes the shift of water out of cells, activates the endogen natriuretic peptides, suppresses the antidiuretic hormone and improves the cortical and medullary blood flow. The marked improvement in the medullary blood flow is also responsible for the dissipation of medullary hypertonicity, leading to tubular inhibition of salt and water reabsorption, excretion of monovalent and divalent cations (Na⁺, K⁺, Ca²⁺ and Mg²⁺) and anions (PO₄⁻³, HCO₃⁻), inability to concentrate or dilute urine and ultimately, osmotic diuresis. These effects, associated with renal vasodilation caused by local release of prostacyclin, are likely to be involved in the protection of kidney injury.

Under conditions of renal ischaemia, mannitol inhibits the renin–angiotensin system in the renal glomeruli, leading to dilatation of the afferent arteriole and improvement on the glomerular filtration rate in humans and dogs. Although these properties have not been found either in normal animal models or healthy volunteers, they have been applied to prevent acute kidney injury (AKI) in some clinical settings, including cardiac and vascular surgery (cardiopulmonary bypass, aortic cross-clamp), renal transplantation (from cadaveric donors), rhabdomyolysis (with creatine kinase levels >5000 U/L) and obstructive jaundice (e.g., cholestatic liver disease). During ischaemia-reperfusion, this medication also acts as a free-radical scavenger, reducing the possibility of kidney injury. On the other hand, mannitol can increase oxygen consumption by augmenting the reabsorption of tubular solutes, which in turn improves the glomerular filtration rate.

**Acute kidney injury**

Mannitol can also induce nephrotoxicity, particularly when serum osmolarity exceeds 320 mOsm/L. It occurs typically between 12 h and 7 days (usually within the first 48 h) after giving daily or cumulative doses >200 g and 1100 g, respectively, thereby increasing the osmolar gap more than 55 mOsm/kg (see below), with typical prompt response to discontinuance of the treatment and haemodialysis, when appropriate. It is noteworthy that, whereas low doses increase the glomerular filtration rate acting as a renal vasodilator, higher doses tend to cause the opposite effect.

The predisposing factors for nephrotoxicity have been recently identified in patients with acute stroke and intracerebral haemorrhage (ICH). Poor neurological status, concurrent use of diuretics, pre-existing renal impairment, diabetes, higher infusion rates, age >70 years and diastolic blood pressure >110 mmHg have been identified as independent risk factors in two retrospective studies.

Although the underlying mechanisms of AKI are not thoroughly understood, some of the most accepted theories include:

1. The strong diuretic effect resulting from excessive doses of hypertonic mannitol can lead to peripheral vasodilation - with subsequent haemodynamic changes, renal vasoconstriction and osmotic nephrosis (ON) in patients with predisposing risk factors, as depicted in Figure 2. ON has been defined as an isometric tubular vacuolisation, initially accompanied with profound diuresis and natriuresis, and then typically developing oliguric/anuric AKI. Cell vacuolisation primarily occurs in the proximal tubules and is caused by the capability of mannitol to cross tubular cells via pinocytosis, forming vacuoles that eventually fuse with lysosomes. Although the subsequent reduction in the proximal luminal diameter is usually reversible, the sequelae of ON are unpredictable

2. In patients with pre-existing chronic kidney disease, mannitol half-life can also increase from 70 to 100 min to >36 h, thereby causing nephrotoxicity

3. In diabetic patients, the increase in renal blood flow induced by mannitol is unevenly distributed, which results in reduced oxygen delivery to the medulla and predisposes to ischaemic injury

4. When diuretics acting at the LH are concomitantly administered, the compensatory enhancement of sodium reabsorption occurring in the LH caused by the increase on water and salt delivery is prevented, resulting in strong diuresis volume depletion and AKI.

**Fluid and electrolyte imbalances**

**Hyponatraemia**

When plasmatic mannitol concentration increases faster than the renal clearance (e.g., fast load of a high dose of mannitol or renal failure), the serum osmolarity will.
rise and induce hyponatraemia. In fact, following intravenous administration, for each increase in 100 mg/dL in the mannitol concentration, the plasmatic sodium will fall between 1.6 and 2.6 mEq/L, as a result of the osmotic load that induces water movement from the intracellular to the extracellular compartment (hypertonic hyponatraemia). In addition, for each increase of 182 mg/dL in its concentration, the serum osmolality is expected to increase by 10 mOsm/L. Therefore, serum osmolality should be closely monitored and if it reaches 310 mOsm/L, mannitol should be suspended.

Other authors recommend to measure the osmolar gap (mOsm/kg), particularly in patients with renal impairment. The osmolar gap, calculated as the difference between calculated and measured osmolality, can predict the mannitol concentration in blood. Hence, osmolar gaps >55 mOsm/kg (i.e., mannitol concentration >1000 mg/dL) should be avoided, since they have been found to cause renal vasoconstriction. However, the hyponatraemia appears to be self-corrected within 3 h after an infusions of up to 1.4 g/kg.

In cases of induced hyponatraemia and AKI, any attempt to replace the sodium with hypertonic saline infusion will further increase the serum osmolality. Instead, it should be treated with haemodialysis, when appropriate. In patients with normal renal function, the diuresis caused by mannitol should correct the sodium levels.

### Hyperkalaemia

Mannitol has been considered a safe medication when used at low doses (0.25 gm/kg). In fact, no cases of hyperkalaemia have been reported with the use of low doses administered at slow rate. However, it is a potential life-threatening complication and there have been reported cases of intraoperative cardiac arrest, requiring immediate intervention. When administered along with blood, it can induce haemolysis and hyperkalaemia. It can also be caused by the shift of potassium from the intracellular to the extracellular compartment, particularly in patients with renal failure.

Although several theories have been proposed to explain the mechanism of hyperkalaemia, including passive potassium movement across the cell membrane in response to the hypertonic load, dilutional acidosis, haemolysis and strong ion difference, this phenomenon remains poorly understood. The strong ion difference has been defined as the balance between strong cations (Na+, K+, Mg2+ and Ca2+) and strong anions (Cl− and lactate). According to this theory, a balance impairment caused by Na+ reabsorption decrease stimulates H2O dissociation, and hyperkalaemia occurs in response to an increase in the H+ concentration. In addition, hyponatraemia may increase the hyperkalaemia-related cardiotoxicity, although the underlying mechanisms have not been completely elucidated. The effects on potassium levels seem to be related with the dose administered. Accordingly, whereas moderate doses (1 g/kg) tend to cause mild hypokalaemia, high doses (2 g/kg) are associated with hyperkalaemia.

### Other electrolyte imbalances

Hypokalaemic, hypochloraeic alkalosis may be induced by mannitol, following the volume contraction. Metabolic acidosis has also been described, as a result of solvent drag and dilutional acidosis. Repeated administrations, apart from being less effective, can also result in hypernatraemia and hyperosmolarity caused by dehydration and osmotic diuresis, leading to neurologic complications including demyelination syndromes.

### MANNITOL AND THE BRAIN

Hypertonic mannitol was first used by Scharfetter in 1960 for relieving the ICP. Although a 20% solution given intravenously at a dose as low as 0.15–0.20 g/kg over 30–60 min has been considered to be safe, it has been used at doses up to 2 g/kg in a single administration.

Three mechanisms have been proposed to contribute its capability of lowering ICP [Figure 3]. First, it directly improves the CPP, as a result of the transient increase of the CO occurring during the first minutes of administration. When cerebral autoregulation is preserved, the increase on the CPP leads to cerebral vasoconstriction, thereby diminishing the cerebral blood volume (CBV) and ICP. Second, it increases the cerebrovascular resistance (CVR) caused by reflex vasoconstriction of cerebral arterioles, after an initial improvement in the cerebral blood flow (CBF). The effects on the CVR occur within a few minutes of administration as a result of hypervolaemia, which is caused not only by the improvement in the CO but also a decrease of the blood viscosity and haemodilution.

![Figure 3: Three proposed mechanisms of mannitol for lowering the intracranial pressure. First, it improves the cerebral perfusion pressure, as a result of the transient increase of the cardiac output. When cerebral autoregulation is preserved, this improvement causes reflex cerebral vasoconstriction, leading to an increase of the cerebrovascular resistance. Finally, the osmotic gradient generated diminishes the cerebral blood volume and improves the intracranial compliance. All these changes lead to a consistent improvement of the intracranial pressure.](image-url)
These changes are followed by a fall in the CBV, which ultimately decreases the ICP.\textsuperscript{29} Finally, mannitol causes a direct impact on the CBV, as it promotes the shift of water from the intracellular to the extracellular compartment, thus alleviating the cerebral oedema [Figure 3].

The effects on the water movement and the improvement on the intracranial compliance eventually lead to an improvement on the ICP. Contrary to the rheological effects, the osmotic effects are delayed for 15–30 min and may last for 1.5–6 h, when the osmotic gradient equilibrates with the development of cerebral idiogenic osmoles (osmotically active substances produced by astrocytes).\textsuperscript{14,26} Furthermore, mannitol globally improves the CBF and oxygen delivery not only by increasing the CPP (caused by an improvement of the CO and a drop in the ICP) but also diminishing the production and stimulating the reabsorption of cerebrospinal fluid.\textsuperscript{28}

Although the main mechanisms are related to the shift of water from the white matter into the intravascular compartment, its effects in the human brain can be more complex. For instance, it may also increase the CBV and worsen ICP when the rate given exceeds the rate filtered in the kidney.\textsuperscript{18} However, provided that cerebral autoregulation is preserved, the secondary augment in the CPP may result in vasoconstriction and improvement of the ICP [Figure 2]. In addition, the effects on the CBV are independent of the ICP within the range of 0–25 cm H\textsubscript{2}O, when the intracranial compliance is preserved\textsuperscript{27} [Figure 2]. When administered in fast boluses, it causes a dose-related increase of the CBV, both in the grey matter and the large venous sinuses, leading to acute worsening of the ICP.\textsuperscript{27}

Mannitol has been considered to be impermeant to the BBB. However, a small rebound in the ICP can be noted when the solution occasionally passes into the brain.\textsuperscript{3} This is also explained by the generation of idiogenic osmoles, thereby allowing a shift in the gradient of water in the cellular membrane. Therefore, in patients with consistently high ICP requiring prolonged treatment, it has been recommended to carefully wean the hyperosmolar therapy.\textsuperscript{30}

More importantly, in cases of traumatic brain injury (TBI), ICH or vasogenic oedema where the BBB has been disrupted, caution should be taken for administering the smallest dose, guided by the ICP monitoring and the neurological status of the patient.\textsuperscript{27} Some other authors have suggested to avoid the use of mannitol in this scenario, since the cerebral oedema could be worsened.\textsuperscript{14,30}

\textbf{Intracerebral haemorrhage}

The use of mannitol in patients with ICH is not currently recommended, unless there is evidence of symptomatic cerebral oedema and raised ICP.\textsuperscript{31,32}

Several studies have failed to demonstrate any benefit in this population.\textsuperscript{33–35} In a clinical trial involving patients with ICH, no improvement was found in 1-month mortality or functional disability at 3 months, after administering cumulative doses of 700 g per patient over 1 week, regardless the location and size of the haematoma, ventricular extension or midline shift.\textsuperscript{35}

From the results of the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2), which included more than 2800 patients with spontaneous ICH and hypertension that were randomised to standard or intensive blood pressure lowering, Wang \textit{et al.} reported that death or major disability at 90 days were not significantly improved in the mannitol treatment group.\textsuperscript{36} Similarly, in another study patients treated with mannitol had worse neurological outcome at 90 days, compared with those untreated.\textsuperscript{37} The lack of benefit in this population is likely explained by the fact that this medication can penetrate a disrupted BBB, thereby blunting the osmotic effects and in some cases aggravating the cerebral oedema.

\textbf{Acute stroke}

Some authors have proposed the use of mannitol as a brain protector in situations of cerebral ischaemia.\textsuperscript{38,39}

Apart from its positive effects on the CPP, this osmotic agent can also act as a scavenger of hydroxyl radicals, thereby reversing the changes in the BBB permeability and reducing the accumulation of reactive oxygen species in models of ischaemic brain.\textsuperscript{22} It has also been used for reducing the ICP in the context of the management of cerebral oedema following a stroke, but no evidence indicates that it can improve the outcome.\textsuperscript{38,39}

In a multicentre study, a prospective database from patients with ischaemic and haemorrhagic acute stroke admitted within the first 3 days was analysed.\textsuperscript{39} The adjusted odds ratio (OR) for survival in the mannitol group was not significantly different from the untreated group at 1 and 12 months, neither in the ischaemic nor in the haemorrhagic stroke group.\textsuperscript{39}

Furthermore, in a small clinical trial, patients with a large hemispheric infarction and midline shift >10 mm had a small reduction in the CBV restricted to the non-infarcted hemisphere, after administering 1.5 g/kg of mannitol.\textsuperscript{40} These data demonstrate that, since the shrinkage occurred preferentially in the unaffected hemisphere, the midline shift tended to get worse. Thus, more research is needed to analyse its utility in patients with acute stroke.

\textbf{Elective craniotomies: Brain relaxation}

The term brain relaxation was first proposed by Hayes and Slocum to describe the content-space relationship of the intracranial cavity, after opening the dura during
elective craniotomies." Contrary to the concept of ICP, it is a subjective estimation of the brain firmness, usually made by the surgeon, once the cranium has been opened. However, these concepts are intrinsically related, since the raised ICP results from an increased volume of the content that surpasses the capacity of the intracranial space.

In the context of elective supratentorial craniotomies for brain tumour surgery, some authors have used 20% mannitol infusion at scalp incision, to provide intraoperative brain relaxation and facilitate the exposure of deep brain structures. In a randomised clinical trial, brain relaxation was evaluated after administering either 0.7 or 1.4 g/kg of 20% mannitol at scalp incision, in patients undergoing supratentorial brain tumour craniotomy. It was reported significantly better brain relaxation scores with higher doses, suggesting a dose-response relationship, particularly in patients with radiologic midline shift. However, the type and size of the craniotomies were not taken into account in this study.

When compared to equiosmolar hypertonic saline (HTS) in the setting of patients with subarachnoid haemorrhage (SAH) undergoing craniotomy for aneurysm clipping, mannitol provided similar brain relaxation scores. Furthermore, neither mannitol nor HTS have demonstrated any improvement on ICU stays or hospital days. Thus, although mannitol seems to be effective for brain relaxation at intravenous doses of 0.25–1 g/kg, its effects in this setting are still controversial and deserve further investigation.

**Traumatic brain injury**

In an animal model of post-traumatic diffuse brain oedema, Schilte et al. recently studied the structural and physiologic changes after inducing TBI in rats. Mannitol infusion (1 gm/kg 30 min after the injury) showed to improve the brain tissue oxygenation and venous oxygen saturation in the superior sagittal sinus 2 h after inducing the injury, compared to those who received normal saline. When caudoputamen samples were examined post-mortem, the percentage of capillaries surrounded by oedema was significantly lower in the mannitol group. These findings suggest that it can reverse ultrastructure changes induced by TBI, thereby optimising the oxygen utilisation by brain tissue in rodents. It is important to note, however, that BBB was not disrupted in these models.

According to the Brain Trauma Foundation Guidelines Task Force, mannitol should be used to control ICP at doses between 0.25 and 1 g/kg body weight in a single dose, administered over 20–30 min. There are however insufficient data to support regular administration over several days. Likewise, there is a lack of evidence to support the use of intermittent boluses or continuous infusion. In patients with TBI before ICP monitoring, it should be restricted to those with signs of transtentorial herniation or progressive neurologic deterioration.

In a systematic review, the impact of mannitol on mortality in patients with acute TBI has been inconclusive. Results from the clinical trials are summarised in Table 2. Accordingly, the available evidence is insufficient to support the routine use of mannitol in patients with TBI.

**Mannitol versus hypertonic saline**

For decades, mannitol has been considered the gold standard for the treatment of ICP. However, some concerns have been raised regarding its side effects, and over the past few years, HTS has been proposed alternatively. In fact, one of the main advantages of HTS over mannitol is that it does not cause hypovolaemia, which is of particular importance in patients with TBI. Thus, although the sodium concentration tends to normalise after 48 h regardless of the hypertonic solution used, the baseline sodium levels and the underlying disease can help the clinician to choose the hyperosmolar therapy.

HTS has been used in a range of concentrations of 1.7%–29.2%, thereby making difficult to evaluate its optimal dose and concentration in clinical trials.

**Table 2: Clinical trials evaluating the impact on mortality of mannitol in traumatic brain injury**

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Sample size</th>
<th>Intervention group</th>
<th>Control group</th>
<th>RR for death (95% CI)</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schwartz et al.</td>
<td>1984</td>
<td>70</td>
<td>Mannitol 1g/kg plus additional increments</td>
<td>Pentobarbital 10 mg/kg plus continuous infusion</td>
<td>0.85 (0.52-1.38)</td>
<td>1 year</td>
</tr>
<tr>
<td>Smith et al.</td>
<td>1986</td>
<td>77</td>
<td>Mannitol clinical-guided treatment</td>
<td>Mannitol ICP-guided treatment</td>
<td>0.83 (0.55-1.38)</td>
<td>1 year</td>
</tr>
<tr>
<td>Sayre et al.</td>
<td>1996</td>
<td>44</td>
<td>Mannitol pre-hospital administration</td>
<td>Placebo</td>
<td>1.75 (0.48-6.38)</td>
<td>2 h after arrival to hospital</td>
</tr>
<tr>
<td>Vialet et al.</td>
<td>2003</td>
<td>20</td>
<td>20% mannitol 2 ml/kg</td>
<td>Hypertonic saline 7.5% 2 ml/kg</td>
<td>1.25 (0.47-3.33)</td>
<td>3 months</td>
</tr>
</tbody>
</table>

RR=Relative risk, CI=Confidence interval, ICP=Intracranial pressure
Similar to mannitol, it can improve CBF by relaxing the arteriolar vascular smooth muscle and diminishing the cerebral endothelial cell oedema. Some side effects including electrolyte imbalances, volume overload, rebound intracranial hypertension and central pontine myelinolysis have been also described.[4]

The central pontine myelinolysis caused by a sharp increase in the sodium serum concentration is of particular concern when HTS is administered.[30] Accordingly, plasma sodium concentration must be closely monitored, and values >155 mmol/L should be avoided. Moreover, it should be administered through a central line catheter catheter, to avoid the risk of thrombophlebitis.[4]

Although the mechanisms to control raised ICP are similar, HTS is not related to AKI, hyperkalaemia or hyponatraemia.[48] In addition, the reflection coefficient (a term used to describe the relative impermeability to the intact BBB) of HTS is slightly higher compared with mannitol (1.0 and 0.9, respectively).[8,30,44] Therefore, the CBF is consistently improved, thereby counteracting hypoperfusion and vasospasm.[30]

In the setting of TBI, HTS appears to have a number of advantages, including plasma volume expansion, brain cell immune modulation, reduction of extracellular glutamate and CBF improvement.[30] However, these theoretical advantages have not been supported by the available evidence, which is summarised in Table 3.[49-56] In the context of elective craniotomy for supratentorial tumours, equiosmolar doses of 20% mannitol and 3% HTS seem to provide similar relaxation scores, whereas effectively improve ICP and CPP, without significant differences in the haemodynamic response despite the higher urine output observed with mannitol.[45]

Data are limited in other scenarios because of the heterogeneity of the study population, the disparity of sodium formulations, differing inclusion and exclusion criteria and the small sample size of most clinical trials. Therefore, further research is warranted to determine the relative benefits of these two agents. In particular, whether it improves the CPP or modifies the neurological outcome irrespective its undeniable effects on the ICP, remains unknown.[14]

### CONCLUSION

Mannitol has been used in several clinical scenarios in neuroanaesthesia. However, its main effects are dependent on the integrity of the BBB, and the available evidence is scarce to support its routine use in neurocritical patients unless the ICP is elevated despite first-line treatment. A better understanding of its osmotic effects impacting on the cardiovascular system, the kidney and the brain physiology, is essential to optimise its clinical use and improve its safety profile. In most instances, the decision to use mannitol or HTS should be carefully made based on the underlying disease, the sodium levels and the cardiovascular stability of the patient.

Whether mannitol can improve neurological outcomes or has any impact on mortality in patients with TBI is unknown. In addition, some questions remain unanswered regarding the optimal treatment regimen and the alternative use of HTS. Therefore, larger clinical trials are needed to address these crucial aspects of the treatment.

**Table 3: Clinical trials evaluating the effectiveness of mannitol compared to hypertonic saline in patients with severe traumatic brain injury and raised intracranial pressure**

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Sample size</th>
<th>Mannitol dose (%)</th>
<th>HTS dose (%)</th>
<th>Outcome</th>
<th>Effect size</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viallet et al.[53]</td>
<td>2003</td>
<td>20</td>
<td>2 ml/kg (20%)</td>
<td>2 ml/kg (7.5)</td>
<td>Number of episodes per day</td>
<td>Mannitol: 13.3±14.2*</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HTS: 6.8±5.5*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Francony et al.[52]</td>
<td>2008</td>
<td>20</td>
<td>231 ml (20%)</td>
<td>100 ml (7.45)</td>
<td>Difference of means</td>
<td>−4 (95% CI−8.11-0.11)†</td>
<td>0.057</td>
</tr>
<tr>
<td>Oddo et al.[53]</td>
<td>2009</td>
<td>42†</td>
<td>0.75 g/kg (25%)</td>
<td>250 ml (7.5)</td>
<td>PbTO2§</td>
<td>Mannitol: Decreased 2.9 mm Hg§</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HTS: Increased 13.1 mm Hg§</td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Cottenceau et al.[54]</td>
<td>2011</td>
<td>47</td>
<td>4 ml/kg (20%)</td>
<td>2 ml/kg (7.5)</td>
<td>Difference of means</td>
<td>−1.30 (95% CI−6.33-3.73)†</td>
<td>0.612</td>
</tr>
<tr>
<td>Sakellaridis et al.[55]</td>
<td>2011</td>
<td>199‡</td>
<td>2 ml/kg (20%)</td>
<td>0.42 ml/kg (15)</td>
<td>Difference of means</td>
<td>−0.47 (~2.38-1.44)†</td>
<td>0.629</td>
</tr>
<tr>
<td>Jagannatha et al.[56]</td>
<td>2016</td>
<td>450‡</td>
<td>2.5 ml/kg (20%)</td>
<td>2.5 ml/kg (3)</td>
<td>Fall in ICP</td>
<td>Mannitol: 8.9±8.4</td>
<td>0.135</td>
</tr>
</tbody>
</table>

*MeansSD. †Differences of means are reported two hours after the treatment. ‡Number of ICP episodes. §PbTO2: Brain tissue oxygen tension. †Results are given compared to baseline values at 2 h. HTS=Hypertonic saline, SD=Standard deviation, ICP=Intracranial pressure, CI=Confidence interval
Fandino: Clinical use of mannitol in neuroanaesthesia

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES


